Cagrilintide + Semaglutide 5mg blend: Dosage, Reconstitution & Research Protocol Guide

Cagrilintide + Semaglutide 5mg blend Vial Specifications

Peptide

Cagrilintide + Semaglutide (2.5mg/2.5mg Vial) (NNMT inhibitor)

Vial Content

Cagrilintide 2.5 mg + Semaglutide 2.5 mg per vial

Category

Metabolic / Weight Loss

Administration Method

Subcutaneous injection

Common Use Case

Maximum weight loss combining amylin and GLP-1 receptor pathways

Cagrilintide + Semaglutide Mechanism of Action

CagriSema is a fixed-dose combination of cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 receptor agonist). Semaglutide reduces appetite and slows gastric emptying via GLP-1 receptors in the hypothalamus and GI tract. Cagrilintide acts through amylin receptors in the area postrema and hypothalamus to independently signal satiety and slow digestion. Their combined effect on distinct but complementary satiety pathways produces synergistic weight loss that substantially exceeds either agent alone. In Phase 3 REDEFINE trials, the combination achieved approximately 22–25% total body weight reduction over 68 weeks.

Cagrilintide + Semaglutide Research Findings and Observed Outcomes

Findings and reported areas of study for Cagrilintide + Semaglutide (2.5mg/2.5mg Vial) include:

• ~22–25% body weight reduction in Phase 3 clinical trials
• Improved glycemic control and HbA1c reduction
• Greater fat mass loss with preservation of lean body mass compared to GLP-1 monotherapy
• Improvements in cardiometabolic markers (blood pressure, lipids, waist circumference)
• Once-weekly dosing supporting long-term adherence

These observations are discussed for research and educational reference only and are not medical claims.

Cagrilintide + Semaglutide 5mg blend Supplies for Reconstitution and Handling

• •CagriSema 5mg/5mg vial
• •Bacteriostatic water (2 mL)
• •Insulin syringes (29–31 gauge, 1 mL / 100-unit)
• •Alcohol prep pads
• •Sharps container

Supplies listed are for laboratory handling and research preparation purposes only.

Cagrilintide + Semaglutide Injection Route, Frequency and Timing

Cagrilintide + Semaglutide Dosage Ranges

The ranges below pair the listed dose with the draw volume for this product strength.

Cagrilintide + Semaglutide 5mg blend Dosage to Syringe Units

Based on reconstitution below

This dosing table is unique to the 5 mg blend vial. Units refer to markings on a standard U-100 insulin syringe (1 unit = 0.01 mL).

Cagrilintide + Semaglutide 5mg blend Duration by Research Dose

At common research doses, one 5 mg blend vial of Cagrilintide + Semaglutide typically supports:

Initial titration phase. Typically used for the first 4–8 weeks before advancing to the 5mg/5mg vial for maintenance dosing.

Cagrilintide + Semaglutide 5mg blend Reconstitution With Bacteriostatic Water

This section applies specifically to the Cagrilintide + Semaglutide (2.5mg/2.5mg Vial).

Recommended Diluent

Bacteriostatic water

Diluent Volume

2 mL

Final Concentration

1.25 mg/mL of each component (2.5 mg/mL total)

Cagrilintide + Semaglutide and Compatible Research Pairings

In research settings, Cagrilintide + Semaglutide (2.5mg/2.5mg Vial) is sometimes paired with peptides such as:

• MOTS-c: Adds mitochondrial metabolic support and AMPK activation to complement GLP-1/amylin weight loss
• AOD-9604: Targets fat oxidation via beta-3 adrenergic pathways for additional fat loss support

Supporting Factors for Cagrilintide + Semaglutide Research

Factors recorded alongside this protocol include:

• Calorie-aware diet — not required to be severely restrictive; CagriSema significantly reduces appetite
• Regular aerobic exercise to preserve lean body mass during weight loss
• Adequate protein intake (1.2–1.6 g/kg) to support muscle preservation
• Adequate hydration — especially important during dose titration to manage GI side effects

These factors can affect how research observations are interpreted.

Cagrilintide + Semaglutide 5mg blend Tolerability Notes

Generally well-tolerated. GI side effects are most common during titration and typically resolve with continued use.

Some individuals report:

• Nausea (most common, especially in first 4–8 weeks)
• Decreased appetite and early satiety
• Injection site reactions (redness, mild swelling)
• Constipation or diarrhea (usually transient)
• Mild fatigue during initial titration

Cagrilintide + Semaglutide 5mg blend Storage Requirements

Unreconstituted

Refrigerate at 2–8°C; do not freeze. Protect from light.

Reconstituted

Refrigerate at 2–8°C; do not freeze.

Post-Mix Stability

Use within 4 weeks of reconstitution

This peptide is generally not recommended for:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Pregnant or breastfeeding individuals
• Anyone advised otherwise by a qualified healthcare professional

Cagrilintide + Semaglutide 5mg blend Purchasing and Research Supply Notes

Before ordering Cagrilintide + Semaglutide (2.5mg/2.5mg Vial), review the product label, available testing documents, and storage instructions.

Check the ResearchLabs listing for:

• Available testing documents
• Product strength and concentration
• Storage and handling instructions
• Current product availability

Confirm the product strength and storage requirements before ordering. Products are for laboratory research only and are not for human consumption.